Skip to main content

Table 1 Summary of study cases

From: Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas

Case Source Age # Tumor samples Stage Primary tumor samples Intervening Tx/s Recurrent samples (***Time to recurrence) ***Time to/Status last followup
LGSC-2 UHN 57 2 IIIC 2-P* Carboplatin/paclitaxel 2-R (46 mo) 86 mo / AWD
LGSC-3 UHN 51 2 IIIC 3-P* Carboplatin/paclitaxel 3-R (17 mo) 19 mo / AWD
LGSC-4 UHN 66 3 IIIB 4-P Carboplatin 4-R1 (25 mo), 4-R2 (45 mo) 60 mo / DOD
LGSC-5 MDACC 51 2 IIIC 5-P Carboplatin/paclitaxel, letrozole 5-R (37 mo) 53 mo / DOD
LGSC-6 MDACC 41 2 IIIC 6-P Carboplatin/paclitaxel 6-R (24 mo) 87 mo / DOD
LGSC-8 MDACC 33 2 IIIC 8-P Cisplatin/cyclophos-phamide 8-R (7 mo) 12 mo / DOD
LGSC-9** BCCA 51 6 IIIB 9-P1, P2, P3* No treatment 9-R1, R2, R3 (100 mo) 141 mo / DOD
LGSC-10 BCCA 57 8 IV 10-P1, P2, P3, P4* Carboplatin/paclitaxel, radiation 10-R1, R2, R3, R4 (45 mo) 62 mo / DOD
LGSC-11** BCCA 62 2 IIIC 11-P* No treatment 11-R (156 mo) 180 mo / DOD
LGSC-12 BCCA 57 6 IIB 12-P1, P2, P3, P4* Etoposide, tamoxifen, anastrozole 12-R1, R2 (18 mo) 53 mo / DOD
LGSC-13 BCCA 58 2 IIIB 13-P* Carboplatin/paclitaxel 13-R (46 mo) 59 mo / DOD
Mean (Total)   53.1 3.4 (37)      
  1. *normal sample also available; **initial diagnosis of SBT; ***time in months since diagnosis.
  2. Abbreviations: AWD = alive with disease, DOD = dead of disease.